Allogene Therapeutics (NASDAQ: ALLO)

• Pioneer in allogeneic cell therapies for cancer
• Advanced 3 "off the shelf" CAR T programs to human clinical trials and initiated the industry’s first Phase II allogeneic trial

Allogene.com

Back To News